基于数字化医疗的肺癌术后患者心肺功能康复的临床研究

注册号:

Registration number:

ChiCTR2200064000 

最近更新日期:

Date of Last Refreshed on:

2023-07-12 15:26:49 

注册时间:

Date of Registration:

2022-09-23 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于数字化医疗的肺癌术后患者心肺功能康复的临床研究

Public title:

Digital medicine-based postoperative cardiopulmonary rehabilitation of patients with lung cancer: a randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于数字化医疗的肺癌术后患者心肺功能康复的临床研究

Scientific title:

Digital medicine-based postoperative cardiopulmonary rehabilitation of patients with lung cancer: a randomized controlled trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李光琦 

研究负责人:

马学磊 

Applicant:

Li Guangqi 

Study leader:

Ma Xuelei 

申请注册联系人电话:

Applicant telephone:

+86 177 0240 7745

研究负责人电话:

Study leader's
telephone:

+86 134 0841 0416

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

liguangqimed@hotmail.com

研究负责人电子邮件:

Study leader's E-mail:

drmaxuelei@gmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省成都市武侯区国学巷37号

研究负责人通讯地址:

四川省成都市武侯区国学巷37号

Applicant address:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan

Study leader's address:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

四川大学华西医院生物治疗科

Applicant's institution:

West China Hospital of Sichuan University

研究负责人所在单位:

四川大学华西医院生物治疗科

Affiliation of the Leader:

West China Hospital of Sichuan University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022年审(1317)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川大学华西医院生物医学伦理审查委员会

Name of the ethic committee:

Biomedical Ethics Review Committee of West China Hospital, Sichuan University

伦理委员会批准日期:

Date of approved by ethic committee:

2022-08-31 00:00:00

伦理委员会联系人:

陈诗琦

Contact Name of the ethic committee:

Chen Shiqi

伦理委员会联系地址:

四川省成都市武侯区国学巷37号

Contact Address of the ethic committee:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 28 8542 3237

伦理委员会联系人邮箱:

Contact email of the ethic committee:

huaxilunli@163.com

研究实施负责(组长)单位:

四川大学华西医院

Primary sponsor:

West China Hospital of Sichuan University

研究实施负责(组长)单位地址:

四川省成都市武侯区国学巷37号

Primary sponsor's address:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院

具体地址:

武侯区国学巷37号

Institution
hospital:

West China Hospital, Sichuan University

Address:

37 Guoxue Lane, Wuhou District

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西第四医院

具体地址:

人民南路三段18号

Institution
hospital:

West China Fourth Hospital, Sichuan University

Address:

18 3rd Section of Renmin Road South

经费或物资来源:

成都尚医信息科技有限公司

Source(s) of funding:

Chengdu Shangyi Information Technology Co., LTD

研究疾病:

肺恶性肿瘤  

Target disease:

Lung cancer

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1.主要目的 探究基于数字化医疗的肺康复运动训练对肺癌术后患者心肺功能恢复的作用。 2.次要目的 (1)评估基于数字化医疗的肺癌术后康复运动训练患者的生活质量、疲劳指数、心理状态、肌力和不良事件。 (2)为肺癌胸腔镜术后患者建立康复基线数据库,探索运动干预模式。  

Objectives of Study:

1. Main purpose: To explore the effect of digital medicine-based postoperative cardiopulmonary rehabilitation on the recovery of cardiopulmonary function in patients with lung cancer. 2. Secondary purpose: (1) To evaluate the quality of life, fatigue index, mental state, muscle strength and adverse events of patients undergoing postoperative rehabilitation exercise training for lung cancer surgery based on digital medicine. (2) Establish a baseline rehabilitation database for patients with lung cancer after thoracoscopic surgery, and explore the mode of exercise intervention.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.认知功能障碍或心理疾病导致不能理解研究内容的患者; 2.已经在过去3个月进行有组织的有氧训练的患者; 3.严重骨科、心血管、心肺疾病、不能定期运动患者。 1) 合并未控制的高血压(静息血压>180/110mmHg)、高血糖/低血糖(反复出现血糖>15.6mmol/L或<3.8mmol/L); 2) 合并其他心血管疾病:心律失常(频发室性早搏、室性心动过速、II度II型及III度房室传导阻滞、未控制的房性心动过速、心脏附壁血栓形成、室壁瘤、心脏乳头肌功能失调或断裂、严重的窦性心动过缓及窦性停搏等)、心力衰竭、中重度狭窄性心脏瓣膜病、肥厚性心肌病或其他形式的流出道狭窄、急性心肌炎、心包炎、活动性心内膜炎、怀疑或已知动脉瘤破裂、急性肺栓塞或肺梗死、心脏停搏史等; 3) 合并有症状的或已经诊断的肺部疾病(如慢性阻塞性肺病等); 4) 合并急性非心源性疾病,如感染、发热、肾功能衰竭、甲状腺功能亢进等; 5) 合并抑郁、焦虑等心理障碍; 6) 合并其他运动可能加重的神经、肌肉、骨骼、风湿性疾病等; 7) 合并未纠正的生理异常状态,如中重度贫血、严重电解质紊乱(如低钾血症、高钾血症、低镁血症等); 4.无法签署知情同意书的患者

Exclusion criteria:

1. Patients with cognitive dysfunction or mental illness who cannot understand the research content; 2. Patients who have performed organized aerobic training in the past 3 months; 3. Patients with serious orthopedic, cardiovascular and cardiopulmonary diseases who cannot exercise regularly; 1) Combination of uncontrolled hypertension (resting blood pressure >180/110 mmHg), hyperglycemia/hypoglycemia (recurrent blood glucose >15.6 mmol/L or <3.8 mmol/L); 2) Combination of other cardiovascular diseases: cardiac arrhythmias (frequent premature ventricular beats, ventricular tachycardia, type II and III atrioventricular block, uncontrolled atrioventricular tachycardia, cardiac appendage thrombosis, ventricular wall tumors, dysfunction or rupture of papillary muscles of the heart, severe sinus bradycardia and sinus arrest, etc.), heart failure, moderately or severely stenotic heart valve disease, hypertrophic cardiomyopathy or other forms of outflow tract stenosis, acute cardiovascular diseases, heart disease (e.g., cardiovascular disease), cardiovascular diseases (e.g., cardioembolic diseases). forms of outflow tract stenosis, acute myocarditis, pericarditis, active endocarditis, suspected or known ruptured aneurysm, acute pulmonary embolism or pulmonary infarction, and history of cardiac arrest; 3) Comorbid symptomatic or diagnosed lung disease (e.g., chronic obstructive pulmonary disease); 4) Comorbid acute non-cardiac illnesses such as infection, fever, renal failure, hyperthyroidism, etc; 5) Comorbid psychological disorders such as depression and anxiety; 6) other neurological, musculoskeletal, skeletal, or rheumatic disorders that may be aggravated by exercise; 7) uncorrected physiological abnormalities such as moderate-to-severe anemia, severe electrolyte disorders (e.g., hypokalemia, hyperkalemia, hypomagnesemia, etc.); 4. Patients unable to sign informed consent.

研究实施时间:

Study execute time:

From 2022-09-26 00:00:00 To 2024-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-09-26 00:00:00 To 2024-06-01 00:00:00

干预措施:

Interventions:

组别:

A项目干预组

样本量:

25

Group:

Intervention group of Project A

Sample size:

干预措施:

软件监督下心肺康复运动

干预措施代码:

Intervention:

Cardiopulmonary rehabilitation exercise under software supervision

Intervention code:

组别:

A项目对照组

样本量:

25

Group:

Control group of Project A

Sample size:

干预措施:

常规术后康复指导

干预措施代码:

Intervention:

Routine postoperative rehabilitation guidance

Intervention code:

组别:

B项目干预组

样本量:

25

Group:

Intervention group of Project B

Sample size:

干预措施:

软件监督下心肺康复运动

干预措施代码:

Intervention:

Cardiopulmonary rehabilitation exercise under software supervision

Intervention code:

组别:

B项目对照组

样本量:

25

Group:

Control group of Project B

Sample size:

干预措施:

常规术后康复指导

干预措施代码:

Intervention:

Routine postoperative rehabilitation guidance

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院 

单位级别:

三级甲等 

Institution
hospital:

West China Hospital, Sichuan University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西第四医院 

单位级别:

三级甲等 

Institution
hospital:

West China Fourth Hospital, Sichuan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

心肺功能 (CPET实验VO2peak)

指标类型:

主要指标

Outcome:

Cardiorespiratory fitness (VO2peak in CPET test )

Type:

Primary indicator

测量时间点:

测量方法:

CPET

Measure time point of outcome:

Measure method:

指标中文名:

肺功能

指标类型:

次要指标

Outcome:

Lung function

Type:

Secondary indicator

测量时间点:

测量方法:

肺功能

Measure time point of outcome:

Measure method:

Lung function

指标中文名:

心功能

指标类型:

次要指标

Outcome:

Heart function

Type:

Secondary indicator

测量时间点:

测量方法:

心脏彩超、心电图

Measure time point of outcome:

Measure method:

Cardiac ultrasound, electrocardiogram

指标中文名:

肿瘤标志物

指标类型:

次要指标

Outcome:

Tumor marker

Type:

Secondary indicator

测量时间点:

测量方法:

肿瘤标志物

Measure time point of outcome:

Measure method:

Tumor marker

指标中文名:

肌力

指标类型:

次要指标

Outcome:

Muscle strength

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心肝肾损伤

指标类型:

次要指标

Outcome:

Heart, liver and kidney injury

Type:

Secondary indicator

测量时间点:

测量方法:

心肌损伤标志物;肝肾功能

Measure time point of outcome:

Measure method:

myocardial injury markers;liver and kidney function

指标中文名:

生活质量

指标类型:

次要指标

Outcome:

Quality of life

Type:

Secondary indicator

测量时间点:

测量方法:

量表

Measure time point of outcome:

Measure method:

scales

指标中文名:

心理躯体症状

指标类型:

次要指标

Outcome:

Psychological and physical symptoms

Type:

Secondary indicator

测量时间点:

测量方法:

安德森症状评估量表、生活质量量表(EORTC-QLQ-C30)、多维疲劳症状量表(MFSI-SF中文改良)、匹茨堡睡眠质量指数评估、医院用焦虑抑郁量表(HADS)、周围神经病变量表

Measure time point of outcome:

Measure method:

Anderson Symptom Assessment Scale; Quality of Life Questionnare-Core 30; Multidimensional Fatigue Symptom Scale (Chinese Modified); Pittsburgh Sleep Quality Index Assessment, Hospital Anxiety and Depression Scale (HADS), Peripheral Neurology Variable Scale

指标中文名:

疾病进展

指标类型:

次要指标

Outcome:

Disease progression

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

次要指标

Outcome:

Routine blood test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

运动相关不良事件

指标类型:

次要指标

Outcome:

Exercise-related adverse events

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

Null

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

实验开始前由不参与实验的独立人员使用SPSS软件生成随机数字和分组信息,并使用信封法隐蔽。患者依据入组顺序和对应的随机数字分组决定实际入组情况。

Randomization Procedure (please state who generates the random number sequence and by what method):

Before the start of the experiment, an independent person who does not participate in the experiment will use SPSS software to generate random numbers and grouping information, and conceals them using the envelope method. The actual enrollment of patients is determined according to the order of enrollment and grouping information of random number table.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

对统计分析者单盲

Blinding:

Single-blind for statistical analysts

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

无(请阅读网站首页注册指南共享原始数据的方式内容)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NA

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

使用病例记录表进行数据收集。研究资料将保存在四川大学华西医院,研究者、研究主管部门、伦理审查委员会可查看。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection was performed using case record forms. The research materials will be kept in West China Hospital of Sichuan University, and can be viewed by investigators, research authorities, and ethics review committees.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-09-23 12:22:18